AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on February 11, 2025, announced that its independently developed mRNA shingles vaccine has been submitted for ...

AIM Vaccine Co., Ltd., a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to ...

Inc. (NYSE American: AIM) has announced its intention to develop Ampligen as a vaccine adjuvant for avian influenza. This ...

AIM ImmunoTech Inc. announced plans to advance its drug Ampligen as a vaccine adjuvant for avian influenza, marking a new initiative in its antiviral development pipeline. The company has ...

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...

The bills would restrict how employers treat vaccination and require a reporting system for "vaccine injuries." ...

Volunteers in north Wales are among 25,000 people taking part in a global trial to find a vaccine against the symptoms of the ...

HONG KONG SAR – media OutReach Newswire – 5 February 2025 – AIM Vaccine Co., Ltd. (06660), a leading PRC vaccine company, announced today that its independently developed mRNA RSV ...

(MENAFN- Dubai PR Network) data-text="AIM Vaccine mRNA RSV Vaccine Submits for Clinical Trials in the U.S." data-link=" Vaccine mRNA RSV Vaccine Submits for Clinical Trials in the U.S." class ...

The issuer is solely responsible for the content of this announcement.